Suppr超能文献

通过使用不同萃取介质的加速试验评估药用玻璃容器的分层倾向。

Delamination propensity of pharmaceutical glass containers by accelerated testing with different extraction media.

作者信息

Guadagnino Emanuel, Zuccato Daniele

机构信息

Scientific Advisor for Stevanato Group, Via Molinella 17, Piombino Dese (PD) 35017-Italy.

出版信息

PDA J Pharm Sci Technol. 2012 Mar-Apr;66(2):116-25. doi: 10.5731/pdajpst.2012.00853.

Abstract

UNLABELLED

The delamination of pharmaceutical glass is a serious issue, as it can cause glass particles to appear in vials, a problem that has forced a number of drug product recalls in recent years. In Type I pharmaceutical glass vials, delamination occurs generally at the bottom and shoulder, where extensive flaming during the conversion process can favor a strong evaporation of alkali and borate species and the formation of heavily enriched silica layers. The contact with parenteral preparations dissolved in an alkaline medium increases the rate of glass corrosion, while the differential hydration of these layers can cause the detachment of flakes. The purpose of this study was to investigate the effect of the pH and the composition of the extraction solutions on the propensity of different glass types to delaminate. Repeated autoclave extractions at 121 °C were carried out on different glass types with different extraction media, including organic extractants like citric and glutaric acid. When vials were in contact with alkaline solutions and similarly aggressive media, an increase in silica extraction values indicated glass corrosion and an increasing risk for further delamination. Under such conditions expansion 33 glass is extensively corroded, showing high silica concentration and heavy flaking as compared to other glass types. Sulfur-treated glass also showed early flaking, even if SiO(2) concentration was very low. A similar ranking was observed with extractions carried out with glutaric and citric acids, but at far much higher SiO(2) concentration levels. Extractions with 0.9% KCl solution can be used as an accelerated test to highlight the propensity of a glass to delaminate, but in no case it can be taken as a guarantee that the glass will not delaminate when exposed to the pharmaceutical drug, whose extraction ability requires case-by-case study.

LAY ABSTRACT

How can injectable drug manufacturers prevent glass delamination? The issue of delamination is a serious one, as it can cause glass particles to appear in vials, a problem that has forced a number of drug product recalls in recent years. To combat this, pharmaceutical and biopharmaceutical manufacturers need to understand the reasons for glass delamination. The most recent cases of product recall due to the presence of particles in the filling liquid have involved borosilicate glass containers carrying drugs made of active components with known ability to corrode glass and to dissolve the silica matrix. Sometimes these ingredients are dissolved in an alkaline medium that dramatically increases the glass corrosion and potentially causes the issue. As this action is strongly affected by time and temperature, flaking may become visible only after a long incubation during storage and requires systematic monitoring to be detected at its early stage. If the nature of the filling liquid is the driving force of the phenomenon, other factors are of primary importance. The surface morphology created during vial forming is a key issue, being a function of the forming temperature that is higher in the cutting step and the forming of the bottom. Delamination occurs generally on the vial's bottom and shoulder, where extensive flaming can favor a strong evaporation of alkali and borate species and the formation of heavily enriched silica layers. When these layers are in contact with a solution, they are subject to a differential re-hydration that may result in cracking and detachment of scales. The purpose of this investigation is to identify testing conditions and parameters that can be used as indicators of an incipient delamination process. Extractions with 0.9% KCl solution for 1 h at 121 °C can be used to simulate a long-term contact with aggressive pharmaceutical preparations, while SiO(2) concentration in the extract solution can be taken as an index of glass dissolution. The conclusions developed by this study can provide pharmaceutical manufacturers with information needed to help prevent glass delamination in their processes.

摘要

未标注

药用玻璃的分层是一个严重问题,因为它会导致小瓶中出现玻璃颗粒,这一问题近年来已迫使多次药品召回。在I型药用玻璃瓶中,分层通常发生在底部和肩部,在转换过程中的大量火焰处理会促使碱和硼酸盐物质强烈蒸发,并形成高度富集的二氧化硅层。与溶解在碱性介质中的肠胃外制剂接触会增加玻璃腐蚀速率,而这些层的不同程度水合作用会导致薄片脱落。本研究的目的是调查萃取溶液的pH值和组成对不同类型玻璃分层倾向的影响。在121°C下对不同类型玻璃使用不同萃取介质(包括柠檬酸和戊二酸等有机萃取剂)进行反复高压灭菌萃取。当小瓶与碱性溶液及类似的侵蚀性介质接触时,二氧化硅萃取值的增加表明玻璃发生腐蚀,进一步分层的风险也在增加。在这种条件下,33号膨胀玻璃被广泛腐蚀,与其他类型玻璃相比,显示出高二氧化硅浓度和严重剥落。经硫处理的玻璃也显示出早期剥落,即使二氧化硅浓度非常低。用戊二酸和柠檬酸进行萃取时也观察到类似的排序,但二氧化硅浓度水平要高得多。用0.9%氯化钾溶液进行萃取可作为一种加速试验,以突出玻璃分层的倾向,但在任何情况下都不能保证玻璃在接触药品时不会分层,药品的萃取能力需要逐案研究。

摘要

注射用药品制造商如何防止玻璃分层?分层问题很严重,因为它会导致小瓶中出现玻璃颗粒,这一问题近年来已迫使多次药品召回。为解决这一问题,制药和生物制药制造商需要了解玻璃分层的原因。最近因灌装液中存在颗粒而导致产品召回的案例涉及硼硅酸盐玻璃容器,这些容器盛装的药品含有已知会腐蚀玻璃并溶解二氧化硅基质的活性成分。有时这些成分溶解在碱性介质中,会显著增加玻璃腐蚀并可能导致该问题。由于这一作用受时间和温度强烈影响,剥落可能仅在储存期间长时间孵育后才会显现,并且需要系统监测才能在早期阶段检测到。如果灌装液的性质是该现象的驱动力,那么其他因素也至关重要。小瓶成型过程中产生的表面形态是一个关键问题,它是切割步骤和底部成型中较高成型温度的函数。分层通常发生在小瓶的底部和肩部,大量火焰处理会促使碱和硼酸盐物质强烈蒸发,并形成高度富集的二氧化硅层。当这些层与溶液接触时,它们会经历不同程度的再水合作用,这可能导致鳞片开裂和脱落。本研究的目的是确定可用作初始分层过程指标的测试条件和参数。在121°C下用0.9%氯化钾溶液萃取1小时可用于模拟与侵蚀性药物制剂的长期接触,而萃取溶液中的二氧化硅浓度可作为玻璃溶解的指标。本研究得出的结论可为制药制造商提供所需信息,以帮助防止其生产过程中的玻璃分层。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验